You have answers in black and white directly from the company. It's your interpretation of what's written that remains waaay off the mark. Also, this msg board has never had a large number of regular participants. Breathtec/Algernon has never captured the interest of the masses like a pot stock and now even a Psychedelic stock. That's a management problem not a msg board participation problem. If they had a "Winning Strategy" (a King Cobra quote) this msg board would likely be lit up like Christmas. Instead, you can always expect a lump of coal stuffed in your stock-ing @ Algernon Pharmaceuticals Inc. Management has driven the bus over the cliff and shareholders remain under the wreckage. Don't expect anyone to get too excited about Phase 1 clinical trials in 2023 and 2024 - because "Everybody Wants In At Phase 2" in 2026 or 2027 for data readouts.
News 
Market Data 
Discover 
